Related Experiment Video
Updated: Aug 13, 2026
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Precision targeting of stromal states in pancreatic cancer: a clinical perspective
Anna Wolters1, Maarten Bijlsma2, Jai Prakash3
1Bioengineering Technology, Technical Medical Centre, University of Twente, 7500 AE Enschede, The Netherlands.
Abstract:
Desmoplastic stroma defines pancreatic ductal adenocarcinoma (PDAC), a highly lethal malignancy. This stroma drives tumor progression, immune evasion, drug resistance, and poor drug delivery. Although targeting tumor stroma has shown preclinical promise, most clinical trials have failed due to limited translational success. A major hurdle is the stroma's extreme heterogeneity and dynamic nature, meaning uniform treatments fail. Emerging evidence supports the existence of distinct 'stromal states' with differential biological functions and therapeutic vulnerabilities. Characterizing these states provides a framework to stratify patients and guide precise, stroma-directed therapies. This review summarizes the clinical landscape of PDAC stroma-targeting strategies, discusses distinct stromal states, and outlines emerging opportunities to exploit the stroma as a therapeutic axis in PDAC to improve clinical trial outcomes.
Insights
Pancreatic ductal adenocarcinoma (PDAC) stroma drives cancer progression, but its heterogeneity limits treatment success. Identifying distinct stromal states offers a new strategy for precise, stroma-directed therapies in PDAC.
Area of Science:
- Oncology
- Cancer Biology
- Tumor Microenvironment Research
Background:
- Desmoplastic stroma is a hallmark of pancreatic ductal adenocarcinoma (PDAC), a lethal cancer.
- This tumor stroma significantly contributes to PDAC progression, immune evasion, and therapeutic resistance.
- Current stroma-targeting strategies in clinical trials show limited success due to the stroma's heterogeneity.
Purpose of the Study:
- To review current strategies for targeting the PDAC tumor stroma.
- To discuss the concept of distinct, functionally different 'stromal states' within PDAC.
- To explore emerging therapeutic opportunities targeting these stromal states for improved patient outcomes.
Main Methods:
- Literature review of preclinical and clinical studies on PDAC stroma-targeting therapies.
- Synthesis of emerging evidence on the heterogeneity and dynamic nature of the PDAC stroma.
- Analysis of distinct 'stromal states' and their biological functions and therapeutic vulnerabilities.
Main Results:
- The extreme heterogeneity and dynamic nature of PDAC stroma present a major challenge for uniform treatment approaches.
- Evidence suggests the existence of specific 'stromal states' with unique characteristics and vulnerabilities.
- Characterizing these stromal states is crucial for developing effective, personalized, stroma-directed therapies.
Conclusions:
- Understanding distinct PDAC stromal states is essential for advancing stroma-directed therapeutic strategies.
- Stratifying patients based on stromal states can guide the development of more precise and effective treatments.
- Exploiting the stroma as a therapeutic axis holds promise for improving clinical trial outcomes in pancreatic cancer.
